Compare AbCellera Biologics Inc (ABCL) vs Cigna Corp (CI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Cigna Corp — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Cigna Corp trades at $289.83 (market cap $75.82B). The key difference: Cigna Corp is far larger — about 32.3× AbCellera Biologics Inc's market cap, and Cigna Corp pays a 2.18% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CI | |
|---|---|---|
Market Cap | $2.35B | $75.82B |
Sector | Health | Health |
52-Week High | $8.12 | $312.00 |
52-Week Low | $2.78 | $244.41 |
Enterprise Value | $1.99B | $98.92B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Cigna (CI) trades at $286.62, down 0.4% on the day, with a neutral technical signal. The stock shows strong fundamentals with a low P/E of 11.95 and consistent earnings beats, including Q1 2026 EPS of $7.79 versus $7.60 expected. Revenue grew to $273.85B in 2025, and the company is expanding into AI-driven healthcare services, as highlighted by recent news of Evernorth's Pharmacy Forward initiative (PRNewswire, 2026-07-01).
The outlook is positive given analyst consensus with a $338.91 price target and 73.68% buy ratings. Key risks include regulatory challenges, such as the Tennessee prescription access lawsuit (Reuters, 2026-06-12), and volatility in medical cost trends. The stock offers value with a dividend yield supported by a recent $1.56 payout, but investors should monitor execution in specialty pharmacy expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
